NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Centre for Health Technology Evaluation

# Technology Appraisal Committee A meeting minutes

**Minutes:** Confirmed

**Date and time:** Tuesday 9 August 2022, 09:30am

**Location:** Via Zoom Conference Call

## Attendees

Committee members present

1. Dr Jane Adam (Chair) Present for all items
2. Dr Brian Shine (Vice-chair) Present for all items
3. Professor Abdallah Al-Mohammad Present for all items
4. Dr Peter Baker-Gulliver Present for all items
5. Richard Ballerand Present for all items
6. Dr Craig Buckley Present for all items
7. Dr Andrew Champion Present for all items
8. Dr Justin Daniels Present for all items
9. Ana Duarte Present for all items
10. Dr Steve Edwards Present for all items
11. Professor Khalida Ismail Present for all items
12. Dr Fiona MacPherson Smith Present for all items
13. Professor G.J. Melendez-Torres Present for all items
14. Hugo Pedder Present for items 1 to 6.1.3
15. Dominic Pivonka Present for items 1 to 4.2.2, 6 to 6.2.2
16. Dr Mohit Sharma Present for all items
17. Alan Thomas Present for all items

NICE staff present

Henry Edwards, Associate Director Items 1 to 4.2.2

Janet Robertson, Associate Director Items 5 to 6.2.2

Jeremy Powell, Project Manager Items 1 to 4.2.2

Thomas Feist, Project Manager Items 5 to 6.2.2

Joanna Richardson, Heath Technology Assessment Adviser Items 1 to 4.2.2

Mary Hughes, Heath Technology Assessment Adviser Items to 5 to 5.2.2

Rufaro Kausi, Heath Technology Assessment Adviser Items 6 to 6.2.2

Lizzie Walker, Heath Technology Assessment Analyst Items to 1 to 4.2.2

Dilan Savani, Heath Technology Assessment Analyst Items to 5 to 5.2.2

Catherine Spanswick, Heath Technology Assessment Analyst Items 6 to 6.2.2

Adam Storrow, Business Analyst, RIA Present for all items

Emily Eaton-Turner, Technical Analyst, Commercial Risk Assessment Items 1 to 5.2.2

Stephen Norton, Technical Analyst, Managed Access Items to 1 to 4.2.2

Helen Barrett, Senior Medical Editor Items 5 to 5.2.2

Olivia Havercroft, Senior Medical Editor Items 1 to 4.2.2

Ella Fitzpatrick, Public Involvement Adviser, PiP Items 1 to 5.2.2

Emma Gordon, Coordinator, MiP Items 5 to 5.1.3

Rosalee Mason, Coordinator, MiP Items 1 to 4.1.3, 5 to 5.1.3

Laura Kelly, Administrator, COT Present for all items

Rumana Zaman, Administrator, TA Items 1 to 4.2.2

Marcia Miller, Administrator, TA Items 5 to 5.2.2

Ayla Hudson, Apprentice, COT Items 6 to 6.2.2

External assessment group representatives present

Bram Ramaekers, Kleijnen Systematic Reviews (KSR), items 1 to 4.13 & 5 to 5.1.3.

Robert Wolff, Kleijnen Systematic Reviews (KSR), items 1 to 4.1.3 & 5 to 5.1.3.

Rebecca Bresnahan, Liverpool Reviews and Implementation Group, items 6 to 6.1.3.

James Mahon, Liverpool Reviews and Implementation Group, items 6 to 6.1.3.

Clinical, Patient & NHS England experts present

Professor Peter Clark, Cancer Drugs Fund Lead, NHS England, present for all items.

Dr Pippa Corrie, Consultant Medical Oncologist, nominated by MSD, items 1 to 4.1.3

Dr Mark Harries, Consultant in Medical Oncology/Chairman of Melanoma Focus, nominated by Melanoma Focus, items 1 to 4.1.3.

Diane Cannon, Corporate Partnership Director of Melanoma UK, nominated by Melanoma UK, items 1 to 4.1.3.

Michael Yelton, Patient Expert, nominated by Melanoma Focus, items 1 to 4.1.3

Dr Dima El-Sharkawi, Haematology Consultant, nominated by RCPath, items 5 to 5.1.3

Jane Nicholson, CEO of WMUK, nominated by WMUK, items 5 to 5.1.3

Ron Presswood, Patient Expert, nominated by WMUK , items 5 to 5.1.3

## Minutes

### Introduction to the meeting

* 1. The chair welcomed members of the committee and other attendees present to the meeting.
  2. The chair noted apologies from committee members.

### News and announcements

* 1. None.

### Minutes from the last meeting

* 1. The committee approved the minutes of the committee meeting held on Tuesday 12 July 2022

### Appraisal of Pembrolizumab for adjuvant treatment of resected stage 2 melanoma with high risk of recurrence [ID3908]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from Merck Sharp & Dohme (MSD)
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Dr Pippa Corrie declared a direct financial interest as she has received payment for attending advisory boards conducted in the last 2 years by MSD & BMS, and has received speaker fees from BMS, MSD, Novartis, Pierre Fabre relating to melanoma systemic therapies. In addition to this, Pippa Corrie had also declared a direct non-financial interest as the PI for the Keynote 716 trial being conducted at Addenbrooke’s hospital, and an indirect interest as PI for other commercial and non-commercial sponsored trials evaluating melanoma systemic therapies in both the adjuvant and metastatic setting. It was agreed that these declarations would not prevent them from providing expert advice during this discussion.
* Dr Mark Harries declared a direct financial interest, having received honoraria from MSD for advisory boards, speakers’ fees and has also received support towards the costs of attending medical conferences. Dr Harries also highlighted a similar relationship with Exact Sciences, Pierre Fabre, BMS, Novartis, Pfizer, Roche, Eisai, Gilead. It was agreed that this declaration would not prevent them from providing expert advice during this discussion.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by Dr Andrew Champion (Clinical) and Dominic Pivonka (Cost).
  1. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting)
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD).
     2. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10786>

### Appraisal of Zanubrutinib for treating Waldenstrom's macroglobulinaemia [ID1427]

* 1. Part 1 – Open session
     1. The chair welcomed the invited experts, external assessment group representatives, members of the public and company representatives from BeiGene.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* Prior to the meeting, Dominic Pivonka declared a direct financial interest as his employer (AbbVie) has a treatment being evaluated in phase 2 studies for Waldenstrom’s macroglobulinaemia. AbbVie acquired the company which developed ibrutinib (previously available for people with previously-treated Waldenstrom’s macroglobulinaemia via the Cancer Drugs Fund.) It was agreed that this declaration would prevent Dominic Pivonka from taking part in this discussion.
* Dr Dima El-Sharkawi declared a direct financial interest, having received advisory board and honoraria fees from AbbVie, AstraZeneca, Beigene, Janssen and Roche. Dr Dima El-Sharkawi is also a trustee of WMUK. It was agreed this declaration would not prevent them from providing expert advice during this discussion.
  + 1. The Chair led a discussion of the consultation comments presented to the committee. This information was presented to the committee by the chair, Dr Jane Adam.
  1. Part 2 – Closed session (company representatives, clinical and patient experts, external assessment group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Appraisal Consultation Document (ACD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10705>

### Appraisal of Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (Review of TA619) [ID3779]

* 1. Part 1 – Open session
     1. The chair welcomed the invited expert, external assessment group representatives, members of the public and company representatives from Pfizer.
     2. The chair asked all committee members and experts, external assessment group representatives and NICE staff present to declare any relevant interests in relation to the item being considered.
* There were no interests declared for this topic.
  + 1. The Chair led a discussion of the evidence presented to the committee. This information was presented to the committee by [enter lead team names].
  1. Part 2 – Closed session (company representatives, external assessment group representatives and members of the public were asked to leave the meeting).
     1. The committee then agreed on the content of the Appraisal Consultation Document (ACD) or Final Appraisal Determination (FAD). The committee decision was reached by consensus.
     2. The committee asked the NICE technical team to prepare the Final Appraisal Determination (FAD) in line with their decisions.
* Further updates will be available on the topic webpage in due course: <https://www.nice.org.uk/guidance/indevelopment/gid-ta10901>

### Date of the next meeting

The next meeting of the Technology Appraisal Committee A will be held on Tuesday 13 September 2022 and will start promptly at 09:30am.